Targeting KAT6A for new cancer treatments
Official title: KAT6A as a novel druggable target for cancer treatment: mechanisms and therapeutic implications in KAT6A-dependent tumors
Funded at University of Pennsylvania · NIH-11047147 · Data updated 2026-11-12
This study is looking at a protein called KAT6A to see if it can help create new treatments for high-grade serous ovarian cancer and triple-negative breast cancer, with the hope of finding better ways to fight these tough cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $552,763 |
| NIH project number | 1R01CA288850-01A1 |
| Project ID | NIH-11047147 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with high-grade serous ovarian cancer or triple-negative breast cancer.
✕Less likely to help
Patients with cancers not associated with KAT6A or those who do not have high-grade serous ovarian cancer or triple-negative breast cancer may not benefit from this research.
What this research studies
This research investigates the role of KAT6A, a histone acetylation enzyme, as a potential target for treating high-grade serous ovarian cancer and triple-negative breast cancer. By understanding how KAT6A influences tumor growth and immune response, the researchers aim to develop new therapies that can effectively combat these aggressive cancers. The approach involves using advanced systems biology techniques to identify and prioritize specific targets within the KAT6A family, which could lead to innovative treatment options for patients. If successful, this research could pave the way for more effective cancer therapies that specifically address the unique characteristics of these tumors.
Why it matters
Potential benefit: If successful, this research could provide new, targeted treatment options for patients with high-grade serous ovarian cancer and triple-negative breast cancer.
How similar studies have gone: Other research has shown promise in targeting histone acetylation enzymes for cancer treatment, indicating that this approach could lead to significant advancements.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Zhang, Lin — University of Pennsylvania
- Study coordinator: Zhang, Lin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.